New Clinical Trial Explores Osteoporosis Drug as Potential Beta Cell Protector in Early Type 1 Diabetes

City of Hope is recruiting newly diagnosed adults for a study testing whether denusumab, an FDA-approved osteoporosis medication, might help protect and regenerate insulin-producing cells in early Type 1 diabetes.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

Denusumab is an existing FDA-approved drug for osteoporosis being tested in a new way—to see if it can protect beta cells in people with early Type 1 diabetes
This is a Phase 1/2 randomized, double-blind clinical trial, meaning researchers are still evaluating both safety and early effectiveness
The study focuses on people recently diagnosed with Type 1 diabetes who still produce some insulin—not those with long-standing diabetes
Enrollment is open at City of Hope in Los Angeles for adults aged 18–50 who meet eligibility criteria

A New Application for an Existing Drug

City of Hope, a major research center in Los Angeles, is launching a clinical trial to test whether denusumab—a medication already approved by the FDA to treat osteoporosis and bone tumors—might have a new role in Type 1 diabetes. The study will investigate whether denusumab can protect and potentially regenerate beta cells, the insulin-producing cells that are lost during Type 1 diabetes.

Denusumab is a human monoclonal antibody, a type of protein designed to target specific cells or processes in the body. While its established use is in bone health, researchers believe its mechanism might also benefit beta cell preservation in early Type 1 diabetes.

Who Can Participate and What Will Be Studied

The trial is enrolling adults aged 18 to 50 who have been recently diagnosed with Type 1 diabetes and still produce some insulin. This focus on early-stage disease is intentional: the goal is to test whether denusumab can help preserve the remaining beta cell function before it is completely lost.

This is a Phase 1/2 randomized, double-blind, multi-center study. That means researchers are simultaneously evaluating the drug's safety profile and gathering initial data on whether it may improve beta cell function and blood sugar control. Participants will not know whether they receive denusumab or a placebo, and researchers will use rigorous methods to reduce bias.

What Researchers Hope to Learn

If successful, denusumab might do more than just slow beta cell loss. Early research suggests the drug could potentially expand the number of functioning beta cells or help regenerate new ones in people with early Type 1 diabetes. This would represent a different approach than many current therapies, which focus on managing blood sugar after beta cell damage has occurred.

It is important to note that this trial is in its early stages. A Phase 1/2 study is designed to answer basic safety questions and gather preliminary evidence, not to prove that a treatment works. Results from this trial will help determine whether larger, longer studies are warranted.

How to Learn More

If you are an adult aged 18–50 who has been recently diagnosed with Type 1 diabetes, you may be eligible to participate. City of Hope is actively enrolling participants at its Los Angeles location. For details about eligibility, study procedures, and how to enroll, speak with your healthcare provider or contact the research center directly.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.